You are here

Development of a fluorescence liposomal ABCG2 Multidrug Transporter assay

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM109505-01
Agency Tracking Number: R43GM109505
Amount: $363,564.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
One Innovation Drive
Worcester, MA 01605-4307
United States
DUNS: 3231854
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 DONALD MELCHIOR
 (508) 754-6700
 donald.melchior@glsynthesis.com
Business Contact
 GEORGE WRIGHT
Phone: (508) 754-6700
Email: george.wright@glsynthesis.com
Research Institution
 Stub
Abstract

ABSTRACT In this project we propose to exploit the recent successful isolation and reconstitution of the important ATP- dependent drug efflux transporter, ABCG2 (BCRP, Breast Cancer Resistance Protein), and combine it with a new transport assay system, the Fluorosome platform, to characterize the interaction of ABCG2 with drugs and drug candidates. The result will provide a useful, novel, highly specific and rapid in vitro transport assay for future general use. We shall employ this assay together with ATPase studies to characterize a wide variety of ABCG2 substrates and modulators. Additionally, by means of this unique construct we shall screen the 89 anticancer drugs in the NCI Oncology Drug Set Plate series for inhibition of ABCG2-mediated transport. The ABCG2 protein is a ubiquitous high capacity drug transporter with wide substrate specificity. The White Paper recently issued by the International Transporter Consortium formed to propose industry and FDA standards for studies of drug:transporter inte

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government